Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07890376
Starting soon Phase 2

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

NCT07890376 · tracked via the Priya Life Science USA tracker
Sponsor
Eli Lilly and Company
Phase
Phase 2
Started
2026-11
Last updated
2026-10-22

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

LY4086940Placebo

LY4086940: Administered orally

Placebo: Administered orally

Study summary

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.

Participation in the study will last about 58 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Meet inclusion criteria under Master Protocol CWMM (NCT06143956) Exclusion Criteria: In addition to exclusion criteria under Master Protocol CWMM (NCT06143956) * Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes * Have a laboratory value suggestive of diabetes * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma. * Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss

Primary outcome measure(s)

  • Percent Change from Baseline in Body Weight — Baseline, Week 32

Trial sites (46)

FacilityCityRegionStatus
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa Chandler Arizona
Headlands Research - Scottsdale Scottsdale Arizona
The Institute for Liver Health II dba Arizona Liver Health-Tucson Tucson Arizona
NorCal Medical Research, Inc Greenbrae California
Velocity Clinical Research, Huntington Park Huntington Park California
Peninsula Research Associates Rolling Hills Estates California
Diablo Clinical Research, Inc. Walnut Creek California
Stamford Therapeutics Consortium Stamford Connecticut
New Horizon Research Center Miami Florida
Indago Research & Health Center, Inc Miami Lakes Florida
Suncoast Clinical Research, Inc. New Port Richey Florida
Charter Research - Winter Park Orlando Florida
Charter Research - Lady Lake The Villages Florida
Medical Research Partners Ammon Idaho
Great Lakes Clinical Trials - Ravenswood Chicago Illinois
Iowa Diabetes and Endocrinology Research Center West Des Moines Iowa
Cotton O'Neil Diabetes & Endocrinology Topeka Kansas
Knownwell Needham Massachusetts
Lucida Clinical Trials New Bedford Massachusetts
Headlands Research - Detroit Southfield Michigan
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division Troy Michigan
StudyMetrix Research City of Saint Peters Missouri
Clinvest Headlands Llc Springfield Missouri
Las Vegas Medical Research Las Vegas Nevada
Dent Neurologic Institute Amherst New York
Rochester Clinical Research, LLC Rochester New York
Monroe Biomedical Research Monroe North Carolina
Lucas Research, Inc Morehead City North Carolina
Lucas Research, Inc. New Bern North Carolina
CTI Clinical Research Center Cincinnati Ohio
Tribe Clinical Research, LLC Greenville South Carolina
Quality Medical Research Nashville Tennessee
IMA Clinical Research Austin Austin Texas
Velocity Clinical Research, Dallas Dallas Texas
FutureSearch Trials of Dallas Dallas Texas
Endeavor Clinical Trials San Antonio Texas
Texas Valley Clinical Research Weslaco Texas
Sovah Clinical Research-River District Danville Virginia
Central Washington Health Services Association d/b/a Confluence Health Wenatchee Washington
Cicemo Srl Buenos Aires Argentina

+ 6 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in the USA

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain Recruiting
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). Starting soon
A Study of LY4178256 in Healthy Participants Recruiting
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Active, not recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors Recruiting

Other trials for the same condition

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea Recruiting
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities Recruiting
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo Active, not recruiting
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07890376 on ClinicalTrials.gov ↗ ← All trials in the USA